top of page
AndroFeme®1 represnts a new era in Women's Health in New Zealand
A patient portrayal of an attractive woman over 50 years old relaxing in a pink jumpter. She has flowing grey hair and her eyes are closed showing she feels great to be so well and healthy, thanks to Androfeme1.

A New Era in
Women’s Health
in New Zealand

Patient portrayal

What is AndroFeme®1?

AndroFeme®1, is the first and only effective testosterone therapy for women registered in New Zealand for the treatment of hypoactive sexual desire dysfunction (HSDD) in post menopausal women.⁴

Packaging for AndroFeme®1 with a distinctive pink left hand side of the box container, and Pink AndroFeme 1 logo. Testosterone 1.0% w/v cream 50ml

What is HSDD?

1 in 3 Women between 40-64 will experience HSDD 

HSDD (Hypoactive Sexual Desire Dysfunction) is the most common form of sexual dysfunction in women, defined by persistent and distressing low sexual desire. It can impact emotional well-being, relationships, and overall quality of life.¹⁻³

1 in 3 Women between 40-64 will experience HSDD

Why choose AndroFeme®1?

Specifically formulated for women

I

Administered via a user-friendly applicator

II

Testosterone to help restore levels to those typical before menopause.⁴

III

Clinically proven to be effective with a known

tolerability profile.

IIII

Improvement typically seen within 4–8 weeks.⁴

bottom of page